News & Articles

New research published in Nature Immunology show strong T cell responses in patients recovered from COVID-19

New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus

Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections

Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021

Following successful evaluation by The Liverpool School of Tropical Medicine, the ELISA test will now be made available for COVID-19 researchers

Read this application note to discover how T cell activation assays can help accelerate COVID-19 vaccine development

Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method

A new prognostic tool developed by an international team led by CTI-Bath paves the way for personalized medicine for cancer patients

Watch this on-demand webinar to learn about the latest approaches in single nucleus transcriptomics and ATAC-Seq

The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses

Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions

FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers

Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus

Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

Workflow is quick, simple and scalable for high-throughput antibody detection with high PPA sensitivity and NPA specificity